Profectus BioSciences, Inc. In-Licenses Portfolio of Patents to Support Vesicular Stomatitis Virus-vectored Vaccine for Ebola and Marburg Viruses

Published: Sep 21, 2011

BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today that it has in-licensed a portfolio of patents to support its vaccine program for Ebola and Marburg viruses. Assembled from a number of academic and biopharma sources, the patents provide Profectus with access to the enabling technologies needed to advance its recombinant Vesicular Stomatitis Virus (rVSV) vectored vaccine through commercialization.

Back to news